Neutralization of Clostridium difficile toxin A using antibody combinations.
about
The repetitive oligopeptide sequences modulate cytopathic potency but are not crucial for cellular uptake of Clostridium difficile toxin AAn update on antibody-based immunotherapies for Clostridium difficile infectionMonoclonal Antibody Combinations that Present Synergistic Neutralizing Activity: A Platform for Next-Generation Anti-Toxin DrugsStructural Basis for Antibody Recognition in the Receptor-binding Domains of Toxins A and B from Clostridium difficileNeutralization of Clostridium difficile toxin A with single-domain antibodies targeting the cell receptor binding domainAntibodies for biodefenseBroadly neutralizing anti-influenza virus antibodies: enhancement of neutralizing potency in polyclonal mixtures and IgA backbones.Humanized staphylococcal enterotoxin B (SEB)-specific monoclonal antibodies protect from SEB intoxication and Staphylococcus aureus infections alone or as adjunctive therapy with vancomycinStable IgG-like bispecific antibodies directed toward the type I insulin-like growth factor receptor demonstrate enhanced ligand blockade and anti-tumor activityToxin-specific antibodies for the treatment of Clostridium difficile: current status and future perspectives.Mechanisms mediating enhanced neutralization efficacy of staphylococcal enterotoxin B by combinations of monoclonal antibodiesA Combination of Three Fully Human Toxin A- and Toxin B-Specific Monoclonal Antibodies Protects against Challenge with Highly Virulent Epidemic Strains of Clostridium difficile in the Hamster Model.Novel Clostridium difficile Anti-Toxin (TcdA and TcdB) Humanized Monoclonal Antibodies Demonstrate In Vitro Neutralization across a Broad Spectrum of Clinical Strains and In Vivo Potency in a Hamster Spore Challenge ModelProtection against Clostridium difficile infection with broadly neutralizing antitoxin monoclonal antibodies.Disease-enhancing antibodies improve the efficacy of bacterial toxin-neutralizing antibodiesA Tetraspecific VHH-Based Neutralizing Antibody Modifies Disease Outcome in Three Animal Models of Clostridium difficile Infection.Antibodies for treatment of Clostridium difficile infection.Recombinant Mucin-Type Fusion Proteins with a Galα1,3Gal Substitution as Clostridium difficile Toxin A Inhibitors.Therapies on the horizon for Clostridium difficile infections.Monoclonal antibodies specific for Bacteroides fragilis enterotoxins BFT1 and BFT2 and their use in immunoassays.A mixture of functionally oligoclonal humanized monoclonal antibodies that neutralize Clostridium difficile TcdA and TcdB with high levels of in vitro potency shows in vivo protection in a hamster infection model.Clostridium difficile antibodies: a patent evaluation (WO2013028810).
P2860
Q21135522-F58D042A-E943-4C79-9151-A8B1D4440D17Q26740788-3982A858-C716-4FF2-A037-FACB5337C694Q26863621-50DF045D-6815-4065-B054-33402F14BDCAQ27680788-4E2D66D3-D9CA-4B49-A7F5-F0A5BAEB0FB0Q28302768-56D8AB66-3794-46E0-B518-32B8187B04C6Q28394941-B7DC5204-18D2-40E4-9B90-BED88AC93CF8Q30370793-D5D7393B-E5FD-4FC1-99F5-E8D0E717B0E6Q34315661-E77C1F4E-FF9D-49A0-9A44-A3FF58F0D046Q34575855-6EC1E844-464C-4F91-A6EF-1975D2FF6EEBQ35155775-A8E22EF5-D2F1-4A63-989C-A6A192B42250Q35172579-775F80B6-F0A0-4F00-AF49-0712F26DC306Q35773934-DA9A8ABD-4495-45BF-9600-899D7D32127AQ36060123-0742E15B-2BCF-4D99-B96D-987E93C89171Q36379304-068A2405-2B22-4A80-B3F4-93C94A919576Q36786293-06BCC1E5-EF93-405D-A415-7556421F82C1Q37239550-2EFC9D10-9014-4F51-8B4A-FD4081A1FB4BQ38208794-5C224F66-84F5-438A-9FC7-D1C5624A1F53Q38755916-A51845EB-BF73-4BCF-8F22-C0BC6AE6B4C0Q38757930-151FF14C-030F-43EA-A41C-2BC4D3907C14Q40309635-F33F89E5-F2CD-4A46-9B29-DC1D6D049E85Q41434690-51B7D139-63F0-442E-9C7E-87F6EE84D347Q44715652-2FA49746-D53B-4FAB-98EE-1DA2820F0333
P2860
Neutralization of Clostridium difficile toxin A using antibody combinations.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Neutralization of Clostridium difficile toxin A using antibody combinations.
@en
Neutralization of Clostridium difficile toxin A using antibody combinations.
@nl
type
label
Neutralization of Clostridium difficile toxin A using antibody combinations.
@en
Neutralization of Clostridium difficile toxin A using antibody combinations.
@nl
prefLabel
Neutralization of Clostridium difficile toxin A using antibody combinations.
@en
Neutralization of Clostridium difficile toxin A using antibody combinations.
@nl
P2093
P2860
P356
P1476
Neutralization of Clostridium difficile toxin A using antibody combinations.
@en
P2093
Bruce E Kimmel
Colin Bird
Gary Woodnutt
Geneviève Hansen
Jared Salbato
Jay M Short
Mangala Hariharan
Marikka Elia
Michael Dudley
P2860
P304
P356
10.4161/MABS.2.2.11220
P577
2010-03-01T00:00:00Z